AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$60.35
pos +0.00
+0.00%
Today's Range: 60.12 - 62.68 | ABBV Avg Daily Volume: 7,156,700
Last Update: 01/30/15 - 4:00 PM EST
Volume: 0
YTD Performance: -7.78%
Open: $0.00
Previous Close: $63.12
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,265,381
Market Cap: 100,566,910,849
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 6 6
Moderate Buy 0 0 1 1
Hold 4 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.55 1.65 1.50
Latest Dividend: 0.49
Latest Dividend Yield: 3.11%
Dividend Ex-Date: 01/13/15
Price Earnings Ratio: 27.44
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
27.44 27.40 25.69
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.36% 24.92% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.20 0.00 0.00
Net Income -21.70 0.00 0.00
EPS -23.10 0.00 0.00
Earnings for ABBV:
EBITDA 6.56B
Revenue 18.79B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.85 $1.09 $4.38 $5.10
Number of Analysts 3 3 5 6
High Estimate $0.89 $1.10 $4.40 $5.35
Low Estimate $0.77 $1.08 $4.30 $4.77
Prior Year $0.72 $0.82 $3.32 $4.38
Growth Rate (Year over Year) 17.59% 32.93% 31.81% 16.54%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jan 29, 2015 | 9:46 AM EST

I am adding allocation to healthcare.

updateJP Morgan Healthcare Conf.

Jan 14, 2015 | 6:41 AM EST

JPMorgan Healthcare Conference (Day 3 of 4) - 01/12/15 - 01/15/15 San Francisco, CA

bearishAbbvie downgraded at BofA/Merrill

Jan 9, 2015 | 7:09 AM EST

ABBV was downgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $70 price target. 

By

Bret Jensen

 | Jan 6, 2015 | 10:30 AM EST

They offer a nice shelter for the headwinds now hitting equities.

By

Chris Laudani

 | Dec 30, 2014 | 11:00 AM EST

Its hepatitis C drug will dominate the market.

By

David Katz

 | Dec 26, 2014 | 12:30 PM EST

Its hepatitis C drug is better; the stock trades at a discount.

By

Jim Cramer

 | Dec 23, 2014 | 1:11 PM EST

Stocks that do well when the economy rises are shining.

By

Bret Jensen

 | Dec 23, 2014 | 12:00 PM EST

It has a great long-term future.

By

Jim Cramer

 | Dec 22, 2014 | 1:12 PM EST

It might be good for consumers, but not for the stock.

By

Bret Jensen

 | Dec 11, 2014 | 11:30 AM EST

I would pick up some large caps on any significant dips.

It's been a while since I have shown this chart. For the last 2 years the yields on the Fi...
Ugly end to a challenging week as stocks post around three percent declines for the openin...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.